Evidence map›Paper›PMID 41028642›Full record

ArticleAnnals of surgical oncology2026

Safety and Efficacy of Cisplatin and Doxorubicin Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients with Ovarian Cancer with Peritoneal Metastases: A Multicenter US Phase I Trial.

Brad Nakamura, Rosemary Senguttuvan, Nora H Ruel, Paul H Frankel, Susan E Yost, Sarah Cole, Sue Chang, Alexander Jung, Melissa Eng, Raechelle Tinsley and 11 more

Registry-linked trialAbstract readClinical Trial, Phase IMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04329494 (Safety and Efficacy of Pressurized Intraperitoneal Aerosolized Chemotherapy), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04329494 phase1recruitingnot on this map

Safety and Efficacy of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Ovarian, Uterine, Appendiceal, Colorectal, and Gastric Cancer Patients With Peritoneal Carcinomatosis (PC)

TypeinterventionalSponsorCity of Hope Medical CenterRan2020 to 2028Enrolled49ConditionsClinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Malignant Uterine NeoplasmArmsBiopsy, Cisplatin, Doxorubicin, Fluorouracil, Intraperitoneal Chemotherapy
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Pressurised intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastases: a scoping review of clinical evidence across emerging indications.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Brad NakamuraDepartment of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Rosemary SenguttuvanDepartment of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Nora H RuelDepartment of Computation and Quantitative Medicine, City of Hope National Medical Center, Duarte, CA, USA.
Paul H FrankelDepartment of Computation and Quantitative Medicine, City of Hope National Medical Center, Duarte, CA, USA.
Susan E YostDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA.
Sarah ColeClinical Protocol Development, City of Hope National Medical Center, Duarte, CA, USA.
Sue ChangDepartment of Pathology, City of Hope National Medical Center, Duarte, CA, USA.
Alexander JungDepartment of Diagnostic Radiology, City of Hope National Medical Center, Duarte, CA, USA.
Melissa EngDepartment of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Raechelle TinsleyDepartment of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Timothy SynoldDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA.
Daphne StewartDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA.
Edward WangDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA.
Joshua CohenDepartment of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Jeannine VillellaDepartment of Surgery, Northwell Health, New York, NY, USA.
Richard L WhelanDepartment of Surgery, Northwell Health, New York, NY, USA.
Amit MercheaDepartment of Surgery, Mayo Clinic Florida, Jacksonville, FL, USA.
Danielle K DePeraltaDepartment of Surgery, Northwell Health, New York, NY, USA.
Yanghee WooDepartment of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Mustafa RaoofDepartment of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Thanh Hue DellingerDepartment of Surgery, City of Hope National Medical Center, Duarte, CA, USA. tdellinger@coh.org.

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI STANLEY R. HAMILTON · 1985 to 2026
$86.3M
National Cancer Institute of the National Institutes of Health P30CA033572NCI NIH HHS P30 CA033572
6 · The paper itself

Abstract

backgroundPressurized intraperitoneal aerosolized chemotherapy (PIPAC) is a novel, minimally invasive method of delivering intraperitoneal chemotherapy with promising peritoneal disease control in ovarian cancer.

methodsThis US multicenter prospective phase I trial (NCT04329494) evaluated the safety and efficacy of PIPAC cisplatin 10.5 mg/m

resultsIn total, 15 patients were enrolled. The median prior lines of therapy was 3 (range 1-10). The PIPAC completion rate (≥2 PIPACs) was 86.7%. A total of 76.9% of patients had extraperitoneal disease at baseline. One patient discontinued treatment for toxicity because of deterioration of her baseline Eastern Cooperative Oncology Group 2 performance status. There was one grade 3 abdominal pain, one grade 3 anorexia, and no grade 4 or 5 adverse events. Laparoscopic best response (peritoneal carcinomatosis index) and histologic response (peritoneal regression grading score) occurred in 30.8% and 46.2%, respectively. Radiologic best response (RECIST) was 6.7%, with one partial response and a stable disease rate of 26.7%. Median PFS and OS were 2.3 months (95% confidence interval 1.7-3.2) and 17.1 months (95% confidence interval 5.6-not reached), respectively (n=15).

conclusionsPIPAC-CD is feasible, safe, and well tolerated at academic US centers. OS and PFS were limited in patients with heavily pretreated ovarian carcinoma who underwent PIPAC-CD. Future trials should focus on optimizing PIPAC drug combinations and determining optimal patient selection criteria for ovarian cancer.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsOvarian NeoplasmsPeritoneal NeoplasmsAdultAerosolsAgedCisplatinDoxorubicinFemaleFollow-Up StudiesHumansMiddle AgedPrognosisProspective StudiesSurvival RateUnited StatesAerosolsCisplatinDoxorubicinCisplatinDoxorubicinOvarian cancerPeritoneal metastasesPIPACPressurized intraperitoneal aerosolized chemotherapy

Identifiers

PMID41028642
PMCPMC12689763

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.